1VTRS Stock Chart & Stats
€14.64
€0.25(1.70%)
At close: 4:00 PM EDT
€14.64
€0.25(1.70%)
Day’s Range― - ―
52-Week Range€5.00 - €23.00
Previous CloseN/A
Volume0.00
Average Volume (3M)85.00
Market Cap
€18.02B
Enterprise Value€30.69B
Total Cash (Recent Filing)€1.51B
Total Debt (Recent Filing)€13.63B
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Nov 05, 2026EPS Estimate
0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding1,148,590,800
10 Day Avg. Volume53
30 Day Avg. Volume85
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.99
Price to Sales (P/S)1.02
P/FCF Ratio7.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€17.61Price Target Upside20.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)2.21
Revenue Forecast (FY)€13.01B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationRobust operating and free cash flow provides Viatris with internal funding for debt reduction, shareholder returns, and portfolio investment. The combination of $2.2 billion in free cash flow and strong growth supports financial resilience even while reported earnings are being rebuilt.
Raised Earnings Outlook And Improving MarginsManagement’s raised full-year targets indicate improving execution and confidence in the underlying business. Higher expected EBITDA and EPS, alongside a 57.5% adjusted gross margin and lower operating expenses as a share of revenue, support more durable earnings improvement.
Broad Complex-product And Pipeline PlatformA broad pipeline spanning complex generics, injectables, transdermal products, biosimilars, and branded medicines can support portfolio renewal beyond mature generic products. High approval activity and advancing clinical programs create multiple avenues for sustained product availability and growth.
Bears Say
Persistent Weak Reported ProfitabilityNegative operating profit and net income weaken the quality and predictability of shareholder returns, despite solid cash generation. The history of swings from strong profitability to losses and the decline in gross margin suggest that pricing, product mix, or cost pressures remain unresolved.
Elevated Absolute Debt BurdenDebt reduction is constructive, but the remaining $13.4 billion balance and debt-to-equity near one still constrain financial flexibility. Meaningful leverage can compete with investment and shareholder returns, particularly if profitability remains negative or cash generation weakens.
Competitive And Procurement PressureViatris operates in markets where established brands and generics can face price competition and procurement-driven volume pressure. Pressure on key products can erode revenue quality and margins, while policy changes in China may make growth less predictable across an important region.
Viatris News
1VTRS FAQ
What was Viatris’s price range in the past 12 months?
Viatris lowest stock price was €5.00 and its highest was €23.00 in the past 12 months.
What is Viatris’s market cap?
Viatris’s market cap is €18.02B.
When is Viatris’s upcoming earnings report date?
Viatris’s upcoming earnings report date is Nov 05, 2026 which is in 30 days.
How were Viatris’s earnings last quarter?
Viatris released its earnings results on Aug 06, 2026. The company reported €0.615 earnings per share for the quarter, beating the consensus estimate of €0.536 by €0.079.
Is Viatris overvalued?
According to Wall Street analysts Viatris’s price is currently Undervalued.
Does Viatris pay dividends?
Viatris does not currently pay dividends.
What is Viatris’s EPS estimate?
Viatris’s EPS estimate is 0.57.
How many shares outstanding does Viatris have?
Viatris has 1,148,590,800 shares outstanding.
What happened to Viatris’s price movement after its last earnings report?
Viatris reported an EPS of €0.615 in its last earnings report, beating expectations of €0.536. Following the earnings report the stock price went down -1.906%.
Which hedge fund is a major shareholder of Viatris?
Currently, no hedge funds are holding shares in IT:1VTRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viatris Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€17.61 (20.28% Upside)
€17.61 (20.28% Upside)
Blogger Sentiment
Bullish
IT:1VTRS Sentiment 60%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
79.04%
12-Months-Change
Fundamentals
Return on Equity
2.65%
Trailing 12-Months
Asset Growth
-8.77%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Viatris
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
1VTRS Company Deck
1VTRS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed predominantly positive operational and strategic momentum: the company beat expectations in Q2 on revenue, EBITDA and EPS, raised full-year guidance across key metrics, showed margin improvement, strong cash generation, aggressive capital returns, meaningful pipeline and regulatory progress (Gwyn Lo approval, Nefecon topline, Phase III programs on track). Offsetting this, notable near-term challenges include Nashik manufacturing disruptions (with a $100–$150 million H2 revenue headwind), emerging markets supply constraints, competitive pressure in some developed-market products, and China procurement policy uncertainty that may moderate future growth. Overall, management framed the challenges as mostly short-term and fully considered in the updated guidance while emphasizing long-term growth opportunities and financial flexibility.View all IT:1VTRS earnings summaries1VTRS Net sales Breakdown
64.45% Brands
35.55% Generics
1VTRS Stock 12 Month Forecast
Average Price Target
€17.61
▲(20.28% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Perrigo Company
―
Teva
―
Amneal Pharmaceuticals
―
Alvotech
―